Since April 2017, the European Pharmacopeia allows to produce Water for Injection (WFI) using other methods than distillation. Meanwhile, the additional water quality "Highly Purified Water" (HPW) could be found in the Ph. Eur. but will be removed in April 2019. This means a huge change in the regulatory situation for the pharmaceutical companies. A new Q&A document had been launched by the EMA, but some topics remain unclear. Therefore, the ISPE D/A/CH CoP water and steam has discussed all questions extensively for 1.5 years and written down their position.
This webinar provided insight into the thoughts of the ISPE D/A/CH experts and additionally addresses the following questions:
Listen to Fritz Röder and a team of panelist as they discuss ten of the most asked or most interesting questions from the webinar in April 2019.
Fritz Roeder of Merck is based in Darmstadt, Germany and is an experienced project manager and engineer with broad knowledge in the pharmaceutical industry. He is an experienced speaker and author on a variety of pharmaceutical water topics.
Michael Clever of Roche is based in Penzberg, Germany and is an expert in the field of clean media operations with a strong engineering background in utility plants. He did a lot of research in the field of ultrafiltration and rouging.
Jochen Schmidt based in Basel, Switzerland, is the Process Utilities Lead at CRB. He has been working in the pharmaceutical water sector for more than 20 years with his main focus on the conception, process selection and dimensioning of complete water systems for the generation, storage and distribution of PW, WFI and pure steam.
Did you miss the webinar? Listen to the Water for Injection Using Non-Distillative Methods Webinar. Not a Member of ISPE? Join ISPE to gain access to all of our past webinars – and check out the webinar page to see all of the topics that have been discussed and what’s coming up.
The ISPE Sterile Products Processing Community of Practice (CoP) Steering Committee continues its series of blog posts, where committee members and other contributing subject matter experts dive into the validation and use of essential equipment and processes that drive sterile processing in the pharmaceutical industry. The aim is to provide practical insights that will enhance your...
Per- and polyfluoroalkyl substances (PFAS) have emerged as a major concern in the pharmaceutical industry and beyond. Restricting their use is heavily debated. On the one hand, these “forever chemicals” can pose environmental and human health risks. On the other hand, their unique physical and chemical properties can make them important for pharma and ultimately for helping to enable access to...